Patent coronary artery and myocardial infarction in the era of primary angioplasty: assessment of an old problem in a new setting with data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
2010 (English)In: EuroIntervention, ISSN 1969-6213, Vol. 6, no 5, 590-595 p.Article in journal (Refereed) Published
Aims: The purpose of this study was to evaluate factors that contribute to a patent IRA (infarct - related artery) and the prognostic impact of a patent IRA in patients with ST-elevation myocardial infarction.
Methods and results: Using the Swedish angiography and angioplasty registry (SCAAR) we included all patients with STEMI and one-vessel coronary artery disease who underwent primary PCI of the culprit lesion only from May 2005 to December 2007. A patent IRA was found in 1,104 of 3,284 patients. Patients with an occluded IRA had significantly increased 7-day mortality (HR, 3.03, 95% CI 1.68-5.46, P<0.001). The incidence of an occluded IRA increased with higher age, in patients over 80 years of age (OR, 1.23, 95% CI; 0.92-1.64), lower in patients on lipid-lowering drugs (OR, 0.68, 95% CI; 0.54-0.86) and lower in patients pre-treated with heparin (OR 0.71, 95% CI; 0.60-0.83) or GPIIb/IIIa receptor blockade (OR 0.77, 95% CI; 0.61-0.97). Treatment with acetylsalicylic acid or clopidogrel had no effect on IRA patency.
Conclusions: IRA patency was associated with a lower 7-day mortality. Older STEM I patients and patients not taking lipid-lowering drugs or pre-treated with heparin or GPIIb/IIIa receptor blockers seem to constitute risk groups for having an occluded IRA.
Place, publisher, year, edition, pages
2010. Vol. 6, no 5, 590-595 p.
Coronary angioplasty, acute myocardial infarction prognosis, occlusive disease, reperfusion therapy, spontaneous reperfusion
Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:uu:diva-151843DOI: 10.4244/EIJV6I5A99ISI: 000294135000009PubMedID: 21044912OAI: oai:DiVA.org:uu-151843DiVA: diva2:411457